Cel In most developed countries cardiovascular diseases are one the leading causes of death in humans after age 45. As a rule, thrombotic occlusion occurs in the arterial part of the vascular net. It is necessary to develop a universal form of prophylaxis that would accomplish a general delay of the fatal, mainly arterial occluding thrombosis. Our proposed project is a part of the 'European Concerted Action on Prevention from Thrombosis by rokinase Enhancement' (ECAPTURE). ECAPTURE aims at prophylaxis by reinforcing the natural defence mechanism against thrombosis, i.e. the vascular fibrinolysis, specifically by chronic pharmacological enhancement of the endogenous level of single-chain urokinase-type plasminogen activator (scu-PA). Our project as a part of the ECAPTURE aims to assess the efficacy of scu-PA in the prevention of arterial thrombosis and to determine the mechanisms of scu-PA prophylactic antithrombotic action.Wwe hypothesize that t-PA plays the main role in prevention and lysis of fibrinrich venous thrombi, but scu-PA is mainly responsible for the prevention and lysis of platelet-rich arterial thrombi. Reinforcing of the humoral fibrinolysis by scu-PA administration or enhancement could efficiently prevent an arising of the arterial platelet-dependent thrombosis or induce a rapid dissolution of these thrombi. In this way we expect to compensate the altered vascular fibrinolysis caused by the defective t-PA release and to prevent or delay the fatal, occluding arterial thrombosis.For a resolution of the proposed objectives in each main part of work the experiments in vitro and in vivo will be conducted. These experiments are directed on the solution of question about feasibility and mechanisms of prevention of the arterial, platelet-rich thrombosis by the subthrombolytic doses of scu-PA in blood. Two main problems will be studied: 1) prophylaxis of thrombosis, and 2) the influence of scu-PA on the growth of the preformed thrombi. The solution of this problem allows to develop a novel approach of prevention from the predominant type of thrombosis in human, i.e.aterial thrombosis. Program(-y) IC-PECO/COPERNICUS - Scientific and technological cooperation between the European Community and European non-member countries, 1992- Temat(-y) 0201 - CEEC participation in BIOMEDICAL AND HEALTH RESEARCH programme Zaproszenie do składania wniosków Data not available System finansowania CSC - Cost-sharing contracts Koordynator Nederlandse Organisatie voor Toegepast Natuurwetenschappelijk Onderzoek Wkład UE Brak danych Adres 9,Zernikedreef 2301 CE Leiden Niderlandy Zobacz na mapie Koszt całkowity Brak danych Uczestnicy (1) Sortuj alfabetycznie Sortuj według wkładu UE Rozwiń wszystko Zwiń wszystko Haematological Scientific Center Rosja Wkład UE Brak danych Adres 4A,Novo-Zykovsky Proezd 125167 Moskva Zobacz na mapie Koszt całkowity Brak danych